An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection of Cerebral ß-Amyloid in Individuals With Down Syndrome Compared to Individuals Without Down Syndrome

Trial Profile

An Open-Label, Non-Randomized Study to Evaluate the Efficacy and Safety of BAY 94-9172 (ZK 6013443) Positron Emission Tomography (PET) for Detection of Cerebral ß-Amyloid in Individuals With Down Syndrome Compared to Individuals Without Down Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2014

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Down syndrome
  • Focus Diagnostic use
  • Sponsors Piramal Imaging
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top